- Home
- VNRX vs MAIA Comparison
VNRX vs MAIA Comparison
Compare VNRX & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNRX
- MAIA
- Stock Information
- Founded
- VNRX N/A
- MAIA 2018
- Country
- VNRX United States
- MAIA United States
- Employees
- VNRX N/A
- MAIA N/A
- Industry
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- VNRX Health Care
- MAIA Health Care
- Exchange
- VNRX Nasdaq
- MAIA Nasdaq
- Market Cap
- VNRX 52.4M
- MAIA 56.3M
- IPO Year
- VNRX N/A
- MAIA 2022
- Fundamental
- Price
- VNRX $0.64
- MAIA $1.52
- Analyst Decision
- VNRX Strong Buy
- MAIA
- Analyst Count
- VNRX 5
- MAIA 0
- Target Price
- VNRX $3.88
- MAIA N/A
- AVG Volume (30 Days)
- VNRX 143.7K
- MAIA 436.2K
- Earning Date
- VNRX 08-18-2025
- MAIA 08-19-2025
- Dividend Yield
- VNRX N/A
- MAIA N/A
- EPS Growth
- VNRX N/A
- MAIA N/A
- EPS
- VNRX N/A
- MAIA N/A
- Revenue
- VNRX $1,308,361.00
- MAIA N/A
- Revenue This Year
- VNRX $372.23
- MAIA N/A
- Revenue Next Year
- VNRX $201.80
- MAIA N/A
- P/E Ratio
- VNRX N/A
- MAIA N/A
- Revenue Growth
- VNRX 64.16
- MAIA N/A
- 52 Week Low
- VNRX $0.40
- MAIA $1.40
- 52 Week High
- VNRX $0.94
- MAIA $3.74
- Technical
- Relative Strength Index (RSI)
- VNRX 44.71
- MAIA 38.13
- Support Level
- VNRX $0.60
- MAIA $1.46
- Resistance Level
- VNRX $0.80
- MAIA $1.60
- Average True Range (ATR)
- VNRX 0.05
- MAIA 0.07
- MACD
- VNRX -0.01
- MAIA -0.02
- Stochastic Oscillator
- VNRX 21.00
- MAIA 14.12
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.